Hepatitis B Virus News and Research

RSS

First study to look at birth-cohort screening outcomes for hepatitis C virus

New research indicates that screening people born between 1946 and 1970 for hepatitis C virus instead of current risk-based screening practices is cost effective and could lead to 106,000 fewer cases of advanced liver disease and 59,000 fewer HCV-related deaths. An estimated 1.6 million U.S. residents ages 40 to 64 are infected with HCV but do not know it.

10 May 2011

Merck launches 'Hope Against Hepatitis C' education program

Merck, known as MSD outside the United States and Canada, today announced the launch of Hope Against Hepatitis C, a company initiative to increase awareness, prevention and diagnosis of hepatitis C virus infection.

10 May 2011

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Aethlon Medical, Inc. announces that it has submitted a request to the U.S. Food and Drug Administration for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier in the United States.

10 May 2011

Innovative detection practices may prevent liver diseases

Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.

9 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

The American Gastroenterological Association Research Foundation has announced its 2011 research scholars. The grants have been awarded to four outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

6 May 2011

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

A rebound of the Hepatitis B virus is common in patients receiving nucleoside analogs for chronic hepatitis B, according to a study from U-M hepatologists. But nearly 40% of the rebounds or virological breakthroughs (VBTs) were not related to antiviral drug resistance.

28 Apr 2011

IL28B gene plays a key role in spontaneous HCV clearance in infants

New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.

28 Apr 2011

FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection

Merck announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously that the available data support approval of Merck's investigational medicine VICTRELIS™ (boceprevir) for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infection in combination with current standard therapy.

28 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Quest Diagnostics launches AccuType IL28B test for HCV

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection.

From Quest Diagnostics 18 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Study unravels how interferon-induced factors inhibit viruses

When viruses attack, one molecule more than any other fights back. Interferon triggers the activation of more than 350 genes, and despite the obvious connection, the vast majority have never been tested for antiviral properties.

11 Apr 2011

HALT-C trial reveals high mortality rates among patients with HCV

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

8 Apr 2011

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

7 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011

Hepatitis B Virus News and Research

First study to look at birth-cohort screening outcomes for hepatitis C virus

Merck launches 'Hope Against Hepatitis C' education program

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Innovative detection practices may prevent liver diseases

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

IL28B gene plays a key role in spontaneous HCV clearance in infants

FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Study: HIV infection linked to increased risk of heart failure

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Quest Diagnostics launches AccuType IL28B test for HCV

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Study unravels how interferon-induced factors inhibit viruses

HALT-C trial reveals high mortality rates among patients with HCV

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News